
Alda Huqi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8530701/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Obstructive Coronary Atherosclerosis and Ischemic Heart Disease: An Elusive Link!. Journal of the American College of Cardiology, 2012, 60, 951-956.	1.2	216
2	Activating PPARα Prevents Post–Ischemic Contractile Dysfunction in Hypertrophied Neonatal Hearts. Circulation Research, 2015, 117, 41-51.	2.0	60
3	Effect of Fatty Acids on Human Bone Marrow Mesenchymal Stem Cell Energy Metabolism and Survival. PLoS ONE, 2015, 10, e0120257.	1.1	60
4	Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey. EuroIntervention, 2015, 11, 68-74.	1.4	48
5	Integration of Wall Motion, Coronary Flow Velocity, and Left Ventricular Contractile Reserve in a Single Test: Prognostic Value of Vasodilator Stress Echocardiography in Patients with Diabetes. Journal of the American Society of Echocardiography, 2018, 31, 692-701.	1.2	44
6	Coâ€existence of Distinct Supramolecular Assemblies in Solution and in the Solid State. Chemistry - A European Journal, 2017, 23, 2315-2322.	1.7	28
7	Acute Liver Carnitine Palmitoyltransferase I Overexpression Recapitulates Reduced Palmitate Oxidation of Cardiac Hypertrophy. Circulation Research, 2013, 112, 57-65.	2.0	27
8	Pharmacological approaches to coronary microvascular dysfunction. , 2014, 144, 283-302.		22
9	Acetylation contributes to hypertrophy-caused maturational delay of cardiac energy metabolism. JCI Insight, 2018, 3, .	2.3	21
10	Myocardial ischemia: From disease to syndrome. International Journal of Cardiology, 2020, 314, 32-35.	0.8	19
11	Cardiac hypertrophy in the newborn delays the maturation of fatty acid β-oxidation and compromises postischemic functional recovery. American Journal of Physiology - Heart and Circulatory Physiology, 2012, 302, H1784-H1794.	1.5	15
12	Reduced levels of putative endothelial progenitor and CXCR4+ cells in coronary artery disease: Kinetics following percutaneous coronary intervention and association with clinical characteristics. Thrombosis and Haemostasis, 2009, 101, 1138-1146.	1.8	15
13	Trimetazidine and Other Metabolic Modifiers. European Cardiology Review, 2018, 13, 1.	0.7	14
14	Microvascular Function/Dysfunction Downstream a Coronary Stenosis. Current Pharmaceutical Design, 2013, 19, 2366-2374.	0.9	14
15	Stress Testing After Complete and Successful Coronary Revascularization. Canadian Journal of Cardiology, 2016, 32, 986.e23-986.e29.	0.8	12
16	Persistent Angina. American Journal of Cardiovascular Drugs, 2010, 10, 27-32.	1.0	10
17	Pharmacological Agents Targeting Myocardial Metabolism for the Management of Chronic Stable Angina : an Update. Cardiovascular Drugs and Therapy, 2016, 30, 379-391.	1.3	10
18	Cardiovascular Risk Factors and Timing of Anthracyclines and Trastuzumab Cardiac Toxicity. Anticancer Research, 2019, 39, 5741-5745.	0.5	9

Alda Huqi

#	Article	IF	CITATIONS
19	Independent and Incremental Value of Severely Enlarged Left Atrium in Risk Stratification of Very Elderly Patients With Chronic Systolic Heart Failure. Congestive Heart Failure, 2012, 18, 222-228.	2.0	7
20	Myocardial Deformation Analysis in Contrast Echocardiography: First Results Using Two-Dimensional Cardiac Performance Analysis. Journal of the American Society of Echocardiography, 2013, 26, 1282-1289.	1.2	7
21	Coexistence of Distinct Supramolecular Assemblies in Solution and in the Solid State. Chemistry - A European Journal, 2017, 23, 2235-2235.	1.7	6
22	Therapy Against Ischemic Injury. Current Pharmaceutical Design, 2013, 19, 4597-4621.	0.9	6
23	Coronary Vasospasm and Coronary Atherosclerosis. Journal of the American College of Cardiology, 2012, 59, 663-664.	1.2	5
24	Integrated quadruple stress echocardiography. Minerva Cardioangiologica, 2019, 67, 330-339.	1.2	5
25	OBSTRUCTIVE CORONARY ATHEROSCLEROSIS AND ISCHEMIC HEART DISEASE: AN ELUSIVE LINK!. Rational Pharmacotherapy in Cardiology, 2012, 8, 721-726.	0.3	4
26	Long-Term Follow-Up of Elective Chronic Total Coronary Occlusion Angioplasty. Journal of the American College of Cardiology, 2014, 64, 2707-2708.	1.2	3
27	Reply. Journal of the American College of Cardiology, 2013, 61, 388.	1.2	1
28	Letter by Huqi et al Regarding Article, "Revascularization Decisions in Patients With Stable Angina and Intermediate Lesions: Results of the International Survey on Interventional Strategy― Circulation: Cardiovascular Interventions, 2015, 8, e002176.	1.4	1
29	Control of cardiac fatty acid metabolism in infants with hypoplastic left heart syndrome. Journal of Molecular and Cellular Cardiology, 2018, 124, 91-92.	0.9	1
30	Prediction of Post Percutaneous Coronary Intervention Myocardial Ischaemia. European Cardiology Review, 2016, 11, 85.	0.7	1
31	Relationship of pulmonary hypertension and right ventricular dysfunction with survival of elderly patients with chronic systolic heart failure. European Heart Journal, 2013, 34, 3630-3630.	1.0	Ο
32	Resting heart rate is an independent predictor of left ventricular diastolic dysfunction in obese patients with or without arterial hypertension. European Heart Journal, 2013, 34, P723-P723.	1.0	0
33	Newborns with congenital heart disease and reactive myocardial hypertrophy display altered cardiac energy metabolism and reduced post-surgical functional recovery. European Heart Journal, 2013, 34, P2140-P2140.	1.0	0
34	Cardiac Hypertrophy in Neonates With Congenital Heart Disease Delays Maturational Alterations in Cardiac Energy Metabolism by Modifying Myocardial Acetylation Control. Journal of Cardiac Failure, 2016, 22, S230-S231.	0.7	0
35	Appropriateness of use criteria in echocardiography. Journal of Cardiovascular Medicine, 2017, 18, 635-636.	0.6	0
36	Cardiac hypertrophy suppresses glucose oxidation in newborns with congenital heart defects. Journal of Molecular and Cellular Cardiology, 2017, 112, 138.	0.9	0

Α		۸	1.1	0	1
- A	LU	A	u	υ	

#	Article	IF	CITATIONS
37	P6146Additional prognostic value of left ventricular contractile reserve and coronary flow velocity reserve in diabetic patients with negative vasodilator stress echo by regional wall motion criteria. European Heart Journal, 2017, 38, .	1.0	0
38	Metabolic Therapy for the Ischemic Heart. , 2014, , 237-248.		0
39	Trimetazidine. , 2015, , 153-172.		0